ACADIA Pharmaceuticals v. Aurobindo & MSN: Pimavanserin Patent Win After 1,383 Days
ACADIA Pharmaceuticals secured a plaintiff judgment in the Delaware District Court against MSN Laboratories and a field of generic ANDA filers seeking to launch pimavanserin (Nuplazid) capsules. Claim 26 of US7601740 survived MSN’s double-patenting invalidity challenge, with final judgment entered May 2024 across seven asserted patents.
Delaware Court backs ACADIA’s pimavanserin patent in ANDA battle
Filed in July 2020, ACADIA Pharmaceuticals, Inc. v. Aurobindo Pharma Ltd. et al. (1:20-cv-00985) is a Hatch-Waxman ANDA infringement action venued in the District of Delaware before Judge Gregory B. Williams. ACADIA asserted seven patents — anchored by US7601740 — against a coalition of generic manufacturers, including Aurobindo, Zydus, Hetero, Teva, and MSN entities, each of which had submitted ANDAs seeking FDA approval to market pimavanserin capsules (10 mg and 34 mg), the active ingredient in Nuplazid, ACADIA’s CNS drug approved for Parkinson’s disease psychosis.
The case resolved on the merits in ACADIA’s favour. The decisive legal event was the Court’s December 2023 Memorandum Order denying MSN’s Motion for Summary Judgment of Invalidity of Claim 26 of US7601740 on double-patenting grounds, and simultaneously granting ACADIA’s Cross-Motion for Summary Judgment of No Invalidity. Final judgment under Fed. R. Civ. P. 58 was entered in May 2024, finding MSN’s ANDA No. 214925 submission an act of infringement under 35 U.S.C. § 271(e)(2) and rejecting MSN’s invalidity and non-infringement counterclaims in full.
The 1,383-day duration is consistent with complex multi-defendant ANDA litigation in Delaware, where coordinating schedules across nine defendants and briefing multiple summary judgment rounds typically extends timelines. The public record does not disclose whether settlements were reached with defendants other than MSN before final judgment, nor does it specify what, if any, consent judgments or stipulated orders were entered against the remaining generic filers — questions material to understanding ACADIA’s full enforcement posture.
Filing to Judgment on the merits for Plaintiff in 1383 days
1,383 days — nearly 4 years, longer than the median Hatch-Waxman ANDA trial in Delaware
Judgment for ACADIA: what the merits ruling means for both parties
Summary judgment resolved the invalidity dispute before trial
Rather than proceeding to a full bench trial on invalidity, the Court resolved the double-patenting challenge to Claim 26 of US7601740 at summary judgment — granting ACADIA’s cross-motion and denying MSN’s. This procedural posture means the claim construction and invalidity record were developed on paper, and the court found no genuine dispute of material fact supporting MSN’s double-patenting theory. Final judgment under Rule 58 then crystallised the outcome across infringement and invalidity.
§ 271(e)(2) ANDA infringementACADIA’s ‘740 patent claim survives; generic launch blocked
Final judgment in ACADIA’s favour means MSN is barred from receiving FDA approval to market pimavanserin capsules until the relevant patent term expires, subject to any appeal. The rejection of MSN’s invalidity counterclaim strengthens the enforceability of Claim 26 and signals that ACADIA’s claim scope is defensible against double-patenting attacks — a common tactic in ANDA litigation where a portfolio of closely related patents exists. Attorneys’ fees remain open and could further shift the economic balance.
Generic entry blockedMSN’s ANDA path closed at district level; appeal remains an option
MSN’s counterclaims for non-infringement and invalidity were both rejected, leaving the company without a district-court finding to rely on for FDA approval. The judgment does not foreclose an appeal to the Federal Circuit, and the Court’s fee-deferral mechanism suggests the parties anticipated that possibility. A successful appeal on claim construction or the double-patenting analysis would be required to reopen a path to market for MSN at this stage.
Appeal pathway remains openNuplazid exclusivity reinforced across a seven-patent portfolio
The outcome reinforces ACADIA’s ability to enforce a multi-patent estate around pimavanserin against each of the nine named generic defendants. For the broader CNS generics sector, this case illustrates the difficulty of dislodging a well-constructed ANDA defence built on composition, formulation, and method-of-use patents filed across multiple application dates. Companies holding similar multi-layered CNS portfolios may cite this outcome when structuring their own Hatch-Waxman enforcement strategy.
CNS portfolio enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ACADIA Pharmaceuticals, Inc. | Company | CNS-focused biopharmaceutical company — holder of US7601740 covering pimavanserinSearch in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Consortium of generic pharmaceutical ANDA filers seeking to market pimavanserin capsulesSearch in Eureka ↗ |
| Co-Defendant | Zydus Lifesciences Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Hetero USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Zydus Pharmaceuticals (USA), Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Aubrey James Morin | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Bruce M. Wexler | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Chad J. Peterman | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Charles E. Davis | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Felix A. Eyzaguirre | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Darlington Taylor | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jessica Marie Jones | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michelle Streifthau-Livizos | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Peter E. Conway | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Rebecca A. Hilgar | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Scott F. Peachman | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris James LLP | Law Firm | Representing ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing Arnstein & Lehr LLP | Law Firm | Representing ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Michael P. Hogan | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Timothy H. Kratz | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The final judgment is narrow in scope but commercially decisive: it resolves only the ACADIA–MSN dispute, entering judgment on both infringement under § 271(e)(2) and against MSN’s invalidity and non-infringement counterclaims for Claim 26 of the ‘740 patent. The phrasing ‘all prior rulings, orders, judgments, and findings’ incorporates the December 2023 summary judgment order as the analytical foundation, meaning the merits were determined on the paper record rather than after trial. The explicit fee-deferral language is unusual and suggests the court anticipated an appeal.
US7601740 — Pimavanserin compositions for CNS disorders
US7601740B2 (application no. US10/759561) is the anchor patent in ACADIA’s pimavanserin estate, covering pharmaceutical compositions comprising pimavanserin — a selective serotonin inverse agonist (SSIA) at the 5-HT2A receptor, approved under the brand name Nuplazid for Parkinson’s disease psychosis. The patent’s application date places it in an early phase of ACADIA’s CNS research programme, and Claim 26 — the sole claim at issue in the MSN dispute — survived a double-patenting invalidity challenge, confirming that the claim is independently defensible from related family members.
Strategically, the ‘740 patent anchors a seven-patent assertable portfolio that includes formulation, dosing, and method-of-use claims filed across multiple continuation applications, creating staggered expiry dates that extend ACADIA’s exclusivity runway. For competitors in the atypical antipsychotic and CNS disorder space, this structure presents a layered FTO challenge: designing around any single patent leaves exposure under the remaining six. The case’s outcome confirms that at least Claim 26 of the core composition patent is enforceable and not vulnerable to double-patenting attack in its current form.
Should you run an FTO analysis against US7601740 and ACADIA’s pimavanserin estate?
Any company developing pimavanserin generics, 5-HT2A inverse agonist formulations, or CNS antipsychotic dosage forms in the 10 mg–34 mg capsule range should treat this case as a mandatory FTO trigger. The judgment confirms that Claim 26 of US7601740 is valid and infringed by ANDA-based market entry. With six further asserted patents covering methods, formulations, and dosing, a single-patent FTO is insufficient — the full estate must be mapped against each proposed product configuration.
PatSnap Eureka’s FTO Search Agent enables rapid claim-by-claim mapping across ACADIA’s full pimavanserin patent family, identifying which claims cover your specific formulation parameters and application route. Eureka’s prosecution history analysis can surface any disclaimers or amendments made during prosecution of the ‘740 and related patents that may define claim boundaries not visible from the claim text alone — critical intelligence before any ANDA submission or generic development decision.
Run a freedom-to-operate analysis on US7601740B2 to assess your product’s exposure
Run FTO in Eureka →Similar CNS pharmaceutical ANDA patent cases in Delaware District Court
Delaware District Court ANDA cases involving CNS and antipsychotic drug patents, including multi-defendant infringement actions under 35 U.S.C. § 271(e)(2).
What this case signals for the CNS pharmaceutical IP landscape
A multi-defendant ANDA loss on double-patenting signals how Delaware courts assess layered CNS patent portfolios.
Double-patenting attacks on ANDA targets face a high summary judgment bar
MSN’s double-patenting invalidity argument — a standard ANDA counterclaim — failed at summary judgment, not at trial. This suggests ACADIA’s claim drafting and terminal disclaimer strategy were sufficiently robust to eliminate triable issues. Generic filers targeting multi-patent CNS drugs should stress-test double-patenting positions before committing to litigation.
Multi-defendant ANDA coordination creates settlement opacity for IP teams
With nine defendants, the public record only definitively resolves the MSN dispute. Other defendants’ statuses — settled, dismissed, or subject to consent judgments — are not disclosed in the final judgment. IP teams monitoring competitive freedom-to-operate for pimavanserin generics should obtain the full docket to map each defendant’s outcome individually.
ACADIA v Aurobindo — key questions answered
Final judgment was entered in favour of ACADIA Pharmaceuticals against MSN Laboratories. The court found that MSN’s ANDA No. 214925 submission infringed Claim 26 of US7601740 under 35 U.S.C. § 271(e)(2), and rejected MSN’s counterclaims for non-infringement and invalidity. The judgment was entered May 7, 2024.
The court denied MSN’s motion for summary judgment of invalidity on double-patenting grounds and granted ACADIA’s cross-motion for summary judgment of no invalidity in a December 2023 Memorandum Order. The court found no genuine dispute of material fact supporting the double-patenting theory, suggesting ACADIA’s claim drafting and any applicable terminal disclaimers were sufficient to defeat the challenge at summary judgment.
ACADIA asserted seven patents: US7601740B2, US10953000B2, US10449185B2, US7732615B2, US10646480B2, US10849891B2, and US10517860B2. These cover pimavanserin compositions, formulations, dosing methods, and related pharmaceutical preparations. The final judgment on the merits specifically addresses Claim 26 of US7601740 as it relates to MSN.
The defendants included Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Hetero USA Inc., Hetero Labs Limited, Teva Pharmaceuticals USA Inc., MSN Laboratories Private Limited, and MSN Pharmaceuticals Inc. — nine entities across six generic pharmaceutical groups, each having filed ANDAs for pimavanserin capsules.
The final judgment explicitly deferred any motions for attorneys’ fees and costs under Fed. R. Civ. P. 54 and Local Rules 54.1/54.3, and any motion for an exceptional-case finding under 35 U.S.C. § 285, until 14 days after final disposition of any appeal. This suggests the court anticipated an appeal by MSN and elected not to trigger fee briefing during the pending appellate period.
PatSnap Eureka searches patents and litigation data to answer instantly.